Imagene Partners with Oracle to Launch CanvOI on Oracle Cloud Infrastructure
Oracle and Imagene have launched CanvOI, a state-of-the-art pan-cancer foundation model running on Oracle Cloud Infrastructure (OCI). CanvOI is designed to decode cancer from biopsy images and drive cancer research forward. The model, with 1.1 billion parameters, was pre-trained on over 630,000 tissue images from more than 100 sites, covering 40+ major body organs and tissue types.
CanvOI aims to improve cancer diagnosis and treatment by providing valuable oncology intelligence. It outperforms leading digital pathology foundation models in tasks such as predicting treatment responses, discovering biomarkers, and assessing disease prognosis. The model leverages OCI Supercluster and OCI AI Infrastructure for AI inference computation and large-scale data processing.
Oracle e Imagene hanno lanciato CanvOI, un modello fondazionale pan-cancro all'avanguardia che opera su Oracle Cloud Infrastructure (OCI). CanvOI è concepito per decifrare il cancro a partire da immagini di biopsia e promuovere la ricerca oncologica. Il modello, con 1,1 miliardi di parametri, è stato pre-addestrato su oltre 630.000 immagini di tessuti provenienti da più di 100 siti, coprendo oltre 40 principali organi e tipi di tessuto del corpo.
CanvOI mira a migliorare la diagnosi e il trattamento del cancro fornendo informazioni preziose in oncologia. Supera i principali modelli fondazionali di patologia digitale in compiti come la previsione delle risposte ai trattamenti, la scoperta di biomarcatori e la valutazione della prognosi della malattia. Il modello sfrutta OCI Supercluster e OCI AI Infrastructure per il calcolo dell'inferenza AI e l'elaborazione di grandi volumi di dati.
Oracle e Imagene han lanzado CanvOI, un modelo de fundación pan-cáncer de última generación que opera en Oracle Cloud Infrastructure (OCI). CanvOI está diseñado para decodificar el cáncer a partir de imágenes de biopsias y avanzar en la investigación sobre el cáncer. El modelo, con 1.1 mil millones de parámetros, fue preentrenado con más de 630,000 imágenes de tejido de más de 100 sitios, cubriendo más de 40 órganos y tipos de tejido importantes del cuerpo.
CanvOI tiene como objetivo mejorar el diagnóstico y tratamiento del cáncer al proporcionar valiosa inteligencia oncológica. Supera a los principales modelos de patología digital en tareas como predecir respuestas a tratamientos, descubrir biomarcadores y evaluar el pronóstico de enfermedades. El modelo aprovecha OCI Supercluster y OCI AI Infrastructure para el cálculo de inferencias de IA y el procesamiento de datos a gran escala.
오라클과 이미진은 CanvOI를 출시했습니다. 이는 Oracle Cloud Infrastructure (OCI)에서 운영되는 최첨단 범위형 암 기초 모델입니다. CanvOI는 생검 이미지에서 암을 해독하고 암 연구를 발전시키기 위해 설계되었습니다. 이 모델은 11억 개의 매개변수를 가지고 있으며, 100개 이상의 사이트에서 수집된 630,000개 이상의 조직 이미지로 사전 훈련이 완료되어, 40개 이상의 주요 신체 기관과 조직 유형을 다룹니다.
CanvOI는 귀한 종양학 지능을 제공하여 암 진단과 치료를 개선하는 것을 목표로 하고 있습니다. 치료 반응 예측, 바이오마커 발견 및 질병 예후 평가와 같은 작업에서 최첨단 디지털 병리학 기초 모델을 능가합니다. 이 모델은 AI 추론 계산 및 대규모 데이터 처리를 위해 OCI 슈퍼클러스터 및 OCI AI 인프라를 활용합니다.
Oracle et Imagene ont lancé CanvOI, un modèle fondamental pan-cancer de pointe fonctionnant sur Oracle Cloud Infrastructure (OCI). CanvOI est conçu pour décoder le cancer à partir d'images de biopsie et faire avancer la recherche sur le cancer. Le modèle, avec 1,1 milliard de paramètres, a été pré-entraîné sur plus de 630 000 images de tissus provenant de plus de 100 sites, couvrant plus de 40 organes majeurs et types de tissus corporels.
CanvOI vise à améliorer le diagnostic et le traitement du cancer en fournissant des informations oncologiques précieuses. Il surpasse les principaux modèles de pathologie numérique dans des tâches telles que la prévision des réponses aux traitements, la découverte de biomarqueurs et l'évaluation du pronostic de la maladie. Le modèle tire parti d'OCI Supercluster et d'OCI AI Infrastructure pour le calcul des inférences d'IA et le traitement de grandes quantités de données.
Oracle und Imagene haben CanvOI gestartet, ein hochmodernes pan-krebs Modell, das auf Oracle Cloud Infrastructure (OCI) läuft. CanvOI wurde entwickelt, um Krebs aus Biopsiebildern zu entschlüsseln und die Krebsforschung voranzutreiben. Das Modell umfasst 1,1 Milliarden Parameter und wurde auf über 630.000 Gewebebildern von mehr als 100 Standorten vortrainiert, die mehr als 40 wichtige Körperorgane und Gewebetypen abdecken.
CanvOI zielt darauf ab, die Krebsdiagnose und -behandlung zu verbessern, indem es wertvolle Onkologie-Intelligenz bereitstellt. Es übertrifft führende digitale Pathologiemodelle in Aufgaben wie der Vorhersage von Behandlungsreaktionen, der Entdeckung von Biomarkern und der Bewertung der Krankheitsprognose. Das Modell nutzt OCI Supercluster und OCI AI Infrastructure für KI-Inferenzberechnungen und die Verarbeitung großer Datenmengen.
- Partnership with Oracle provides access to powerful cloud infrastructure for AI computation
- CanvOI outperforms leading foundation models in digital pathology
- Pre-trained on a diverse dataset of 630,000+ tissue images from 100+ sites
- Covers 40+ major body organs and tissue types
- Potential to improve cancer diagnosis and treatment methods
- None.
Insights
The launch of CanvOI on Oracle Cloud Infrastructure represents a significant leap in AI-driven oncology research. This 1.1 billion parameter foundation model leverages OCI's advanced capabilities, including Supercluster and AI Infrastructure technology, to process vast amounts of medical imaging data efficiently.
The model's ability to analyze 630,000+ tissue images from over 100 sites and 40+ major body organs showcases its comprehensive scope. Its performance in various cancer-related tasks, especially with minimal labeled data, addresses a important challenge in biomedical research. This could accelerate discoveries and potentially revolutionize cancer diagnosis and treatment methodologies.
The collaboration between Imagene and Oracle demonstrates the growing trend of specialized AI models being deployed on robust cloud infrastructures, enabling scalability and high-performance computing essential for complex medical research.
CanvOI's introduction marks a pivotal moment in digital pathology and oncology research. Its pan-cancer approach, covering a wide range of organs and tissue types, offers unprecedented potential for comprehensive cancer analysis. The model's ability to predict treatment responses, discover biomarkers and assess prognosis could significantly enhance personalized medicine approaches in oncology.
The OISuite platform, built on CanvOI, democratizes access to advanced AI tools for researchers and diagnostic developers. This could accelerate the pace of discoveries by allowing experts to focus on scientific questions rather than AI technicalities. However, it's important to note that while AI models like CanvOI show promise, their integration into clinical practice will require rigorous validation and regulatory approval processes to ensure patient safety and efficacy.
This partnership between Imagene and Oracle signifies a strategic move in the rapidly growing AI healthcare market. The global digital pathology market, valued at
For Imagene, this collaboration provides access to Oracle's extensive resources and global reach, potentially accelerating market penetration. The OISuite platform could create a new revenue stream through subscription or usage-based models. However, competition in this space is intensifying, with major tech and healthcare companies investing heavily in AI-driven diagnostic tools. Success will depend on CanvOI's performance in real-world applications and its ability to integrate seamlessly into existing healthcare workflows.
CanvOI Oncology Intelligence (OI) foundation model is designed to decode cancer from biopsy images and drive cancer research forward
CanvOI delivers a robust vision data backbone for the development of downstream applications in oncology research, including predicting treatment responses, discovering biomarkers, assessing disease prognosis, and identifying pathological features with state-of-the-art results, outperforming leading foundation models built for digital pathology.
For AI inference computation and to process data at scale, Imagene partnered with Oracle to run CanvOI on OCI, taking advantage of OCI Supercluster and OCI AI Infrastructure technology.
"To transform cancer research, Imagene did what countless other leading AI startups have done – it turned to Oracle's Gen2 AI infrastructure, which delivers the scale and performance required to power the world's largest AI models and help solve humanity's most difficult challenges," said Larry Ellison, Oracle Chairman and CTO. "With CanvOI running on Oracle Cloud Infrastructure, Oracle and Imagene are providing scientists with new weapons in the fight against mankind's deadliest adversary, cancer."
"The next decade holds immense potential for breakthroughs in cancer research driven by Artificial Intelligence," said Dean Bitan, Co-founder and CEO, Imagene. "We designed CanvOI to inspire researchers to dare to explore beyond. This is a pivotal milestone in the fight against this complex and devastating disease. By opening doors for innovative research, we aim to fundamentally change the future of cancer care."
CanvOI, a 1.1 billion parameters foundation model, was pre-trained on a diverse dataset including more than 630,000 tissue images from over 100 sites, covering more than 40 major body organs and tissue types. By applying a new approach to digital pathology foundation models and pushing computational demands differently, CanvOI has achieved industry-leading performance across various cancer-related tasks. Its ability to perform effectively, even with minimal labeled data, is crucial in the biomedical space, where data availability can be challenging.
CanvOI is the cornerstone of Imagene's new OISuite, a platform that supports researchers and diagnostics developers to explore a wide range of questions to conduct in-depth research independently, alleviating the need for AI expertise and extensive data acquisition. OISuite enables rapid discoveries while delivering the highest standards of data privacy and security.
"CanvOI transforms our approach to healthcare and disease understanding," said Dr. David Agus, Founding Director and Co-CEO, Ellison Institute of Technology and Imagene board member. "By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. EIT is committed to leveraging CanvOI to propel groundbreaking innovations in our research that improve patient lives. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition."
Additional Resources
- CanvOI scientific paper, including benchmarks
About Imagene
Imagene is a pioneering company in AI-based precision oncology, dedicated to decoding cancer using biopsy images. Our mission is to unlock the power of Oncology Intelligence to transform cancer research and diagnostics. Imagene's OISuite, powered by our state-of-the-art pan-cancer vision foundation model, enables the development of diverse applications and accelerates discoveries in oncology. LungOI, our AI-based NSCLC multi-gene test, was developed using our foundation model and provides rapid biomarker profiling, facilitating informed clinical decisions.
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
View original content to download multimedia:https://www.prnewswire.com/news-releases/imagene-partners-with-oracle-to-launch-canvoi-on-oracle-cloud-infrastructure-302242989.html
SOURCE Oracle
FAQ
What is CanvOI and how does it relate to Oracle (ORCL)?
How many parameters does the CanvOI model have?
What is the dataset size used to train CanvOI?
How can CanvOI benefit cancer research?
